These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 9765604

  • 1. [AIDS drug in the correct form].
    Schenk M.
    Dtsch Med Wochenschr; 1998 Sep 04; 123(36):A9. PubMed ID: 9765604
    [No Abstract] [Full Text] [Related]

  • 2. [Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine].
    Berezovskaia IuV, Chudinov MV.
    Bioorg Khim; 2005 Sep 04; 31(5):451-65. PubMed ID: 16245688
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA, Reedijk M.
    J Biol Regul Homeost Agents; 1995 Sep 04; 9(3):91-4. PubMed ID: 8782014
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A turning point in the fight against HIV.
    Williams SD.
    ChemMedChem; 2010 Nov 08; 5(11):1799-801. PubMed ID: 20981841
    [No Abstract] [Full Text] [Related]

  • 7. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 08; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
    Naeger LK, Miller MD.
    Curr Opin Investig Drugs; 2001 Mar 08; 2(3):335-9. PubMed ID: 11575701
    [Abstract] [Full Text] [Related]

  • 10. Resistance of HIV to antiretroviral agents. Basic concepts.
    Dianzani F, Antonelli G, Turriziani O.
    J Biol Regul Homeost Agents; 1998 Mar 08; 12(1-2 Suppl):19-22. PubMed ID: 9689574
    [No Abstract] [Full Text] [Related]

  • 11. [Molecular bases in the search for drugs for treating AIDS. Achievements and possible prospects].
    Kraevskiĭ AA.
    Mol Biol (Mosk); 1999 Mar 08; 33(3):343-52. PubMed ID: 10519109
    [No Abstract] [Full Text] [Related]

  • 12. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE, Poirier MC.
    Environ Mol Mutagen; 2007 Mar 08; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
    Kirschberg TA, Balakrishnan M, Huang W, Hluhanich R, Kutty N, Liclican AC, McColl DJ, Squires NH, Lansdon EB.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1131-4. PubMed ID: 18083512
    [Abstract] [Full Text] [Related]

  • 17. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A, Kataropoulou A, Viola M, Zanoli S, La Regina G, Piscitelli F, Silvestri R, Maga G.
    Antiviral Res; 2009 Jan 01; 81(1):47-55. PubMed ID: 18984007
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.
    Antivir Ther; 2000 Mar 01; 5(1):7-14. PubMed ID: 10846586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.